Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure. J of Skin. 2024;8(2):s379. doi:10.25251/skin.8.supp.379